Multiple Myeloma

2 protocols meet the specified criteria


Phase III Study Of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide Or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapy In Patients With Multiple Myeloma (MM) Using Minimal Residual Disease To Direct Therapy Duration (DRAMMATIC Study)


Point-of-care Intervention to Address Financial Toxicity in Patients with Cancer: Provider Interviews